Evidence map›Paper›PMID 41597218›Full record

ReviewCells2026

Hippo Signaling in the Lung: A Tale of Two Effectors-Yap Drives Airway Fate and Taz Drives Alveolar Differentiation.

Rachel Warren, Stijn P J De Langhe

Abstract readReview
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rachel WarrenDepartment of Medicine, Division of Pulmonary and Critical Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Stijn P J De LangheDepartment of Medicine, Division of Pulmonary and Critical Medicine, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-3867-4572

Funding

Cell competition in pulmonary fibrosis and ARDSR35HL161169 · NHLBI · MAYO CLINIC ROCHESTER · PI Stijn Piet Johan De Langhe · 2022 to 2026
$4.7M
Interdisciplinary Training in Lung Physiology and Biomedical EngineeringT32HL105355 · NHLBI · MAYO CLINIC ROCHESTER · PI PRAKASH, Y. S., SIECK, GARY C. · 2012 to 2021
$3.9M
HL-Lung stem cells and their niches.R01HL132156 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DE LANGHE, STIJN PIET JOHAN · 2016 to 2019
$2.0M
Epithelial stem cell hippo signaling in pulmonary fibrosisR01HL146461 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DE LANGHE, STIJN PIET JOHAN · 2019 to 2021
$1.6M
Mayo Clinic Brewer Family Career Development Award (RW). Brewer Family Career Development AwardNational Heart Lung and Blood Institute NIH R35 HL161169 (SDL)NHLBI NIH HHS R01 HL132156NHLBI NIH HHS R01 HL146461NHLBI NIH HHS R35 HL161169NHLBI NIH HHS T32 HL105355
6 · The paper itself

Abstract

The mammalian lung operates under a biological paradox, requiring architectural fragility for gas exchange while maintaining robust regenerative plasticity to withstand injury. The Hippo signaling pathway has emerged as a central "rheostat" in orchestrating these opposing needs, yet the distinct roles of its downstream effectors remain underappreciated. This review synthesizes recent genetic and mechanobiological advances to propose a "Tale of Two Effectors" model, arguing for the functional non-redundancy of YAP and TAZ. We posit that YAP functions to drive airway progenitor expansion, mechanical force generation, and maladaptive remodeling. Conversely, TAZ-regulated uniquely via transcriptional mechanisms and mechanotransduction-acts as an obligate driver of alveolar differentiation and adaptive repair through an NKX2-1 feed-forward loop. Furthermore, we introduce the "See-Saw" model of tissue fitness, where mesenchymal niche collapse releases the mechanical brake on the epithelium, triggering the bronchiolization characteristic of pulmonary fibrosis. Finally, we extend this framework to malignancy, illustrating how Small Cell Lung Cancer (SCLC) subtypes mirror these developmental and regenerative states. This integrated framework offers new therapeutic distinct targets for modulating tissue fitness and resolving fibrosis.

Indexed as

Cell DifferentiationHippo Signaling PathwayLungProtein Serine-Threonine KinasesPulmonary AlveoliTranscription FactorsAnimalsHumansSignal TransductionYAP-Signaling ProteinsProtein Serine-Threonine KinasesTranscription FactorsYAP-Signaling Proteinscell competitionfibrosisHippolung stem cellMycTazYap

Identifiers

PMID41597218
PMCPMC12839984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.